Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma

M. De Lima, K. W. Van Besien, S. A. Giralt, I. F. Khouri, R. Mehra, B. S. Andersson, D. Przepiorka, J. L. Gajewski, M. Korbling, R. E. Champlin

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

We evaluated the response to and toxicity of allogeneic or autologous bone marrow transplantation (BMT) for patients with non-Hodgkin's lymphoma (NHL) who relapsed after autologous BMT. Since 1990, 172 patients have received autologous BMTs for NHL at the MD Anderson Cancer Center and 75 have relapsed. Twelve patients (median age, 42 years), with disease recurrence underwent either allogeneic BMT (eight patients) or a second autologous BMT (four patients). Ten patients received thiotepa, busulfan and cyclophosphamide as conditioning, one patient received cyclophosphamide and total body irradiation and one received BCNU, etoposide, Ara-c and melphalan. The median interval between the first and second transplants was 23.5 months (range 5-80 months). Three patients who underwent allogeneic BMT had refractory relapses, three had a responsive relapse and two were in complete response (CR) at the time of BMT. Five patients received peripheral blood stem cells and three patients, allogeneic bone marrow. Three patients are alive and disease-free at 25, 22 and 7 months after allogeneic BMT. Four patients died of treatment-related causes and one from disease recurrence. All four patients undergoing autologous BMT had responsive relapses. Three patients received peripheral blood stem cells and one patient bone marrow. Two patients are alive and disease-free at 12 and 30 months after autologous transplants. There were no treatment-related deaths; two patients died of disease recurrence. This retrospective study shows that in selected patients, allogeneic or autologous BMT is an effective salvage therapy for NHL which recurs after autologous BMT.

Original languageEnglish (US)
Pages (from-to)121-127
Number of pages7
JournalBone Marrow Transplantation
Volume19
Issue number2
StatePublished - Jan 2 1997
Externally publishedYes

Fingerprint

Autografts
Bone Marrow Transplantation
Non-Hodgkin's Lymphoma
Autologous Transplantation
Recurrence
Homologous Transplantation
Cyclophosphamide
Bone Marrow
Thiotepa
Carmustine
Busulfan
Salvage Therapy
Melphalan
Whole-Body Irradiation
Etoposide

Keywords

  • BMT
  • Lymphoma
  • Relapse

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

De Lima, M., Van Besien, K. W., Giralt, S. A., Khouri, I. F., Mehra, R., Andersson, B. S., ... Champlin, R. E. (1997). Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplantation, 19(2), 121-127.

Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. / De Lima, M.; Van Besien, K. W.; Giralt, S. A.; Khouri, I. F.; Mehra, R.; Andersson, B. S.; Przepiorka, D.; Gajewski, J. L.; Korbling, M.; Champlin, R. E.

In: Bone Marrow Transplantation, Vol. 19, No. 2, 02.01.1997, p. 121-127.

Research output: Contribution to journalArticle

De Lima, M, Van Besien, KW, Giralt, SA, Khouri, IF, Mehra, R, Andersson, BS, Przepiorka, D, Gajewski, JL, Korbling, M & Champlin, RE 1997, 'Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma', Bone Marrow Transplantation, vol. 19, no. 2, pp. 121-127.
De Lima M, Van Besien KW, Giralt SA, Khouri IF, Mehra R, Andersson BS et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplantation. 1997 Jan 2;19(2):121-127.
De Lima, M. ; Van Besien, K. W. ; Giralt, S. A. ; Khouri, I. F. ; Mehra, R. ; Andersson, B. S. ; Przepiorka, D. ; Gajewski, J. L. ; Korbling, M. ; Champlin, R. E. / Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. In: Bone Marrow Transplantation. 1997 ; Vol. 19, No. 2. pp. 121-127.
@article{e9dcb3a373f346f1a63cf205cf66d750,
title = "Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma",
abstract = "We evaluated the response to and toxicity of allogeneic or autologous bone marrow transplantation (BMT) for patients with non-Hodgkin's lymphoma (NHL) who relapsed after autologous BMT. Since 1990, 172 patients have received autologous BMTs for NHL at the MD Anderson Cancer Center and 75 have relapsed. Twelve patients (median age, 42 years), with disease recurrence underwent either allogeneic BMT (eight patients) or a second autologous BMT (four patients). Ten patients received thiotepa, busulfan and cyclophosphamide as conditioning, one patient received cyclophosphamide and total body irradiation and one received BCNU, etoposide, Ara-c and melphalan. The median interval between the first and second transplants was 23.5 months (range 5-80 months). Three patients who underwent allogeneic BMT had refractory relapses, three had a responsive relapse and two were in complete response (CR) at the time of BMT. Five patients received peripheral blood stem cells and three patients, allogeneic bone marrow. Three patients are alive and disease-free at 25, 22 and 7 months after allogeneic BMT. Four patients died of treatment-related causes and one from disease recurrence. All four patients undergoing autologous BMT had responsive relapses. Three patients received peripheral blood stem cells and one patient bone marrow. Two patients are alive and disease-free at 12 and 30 months after autologous transplants. There were no treatment-related deaths; two patients died of disease recurrence. This retrospective study shows that in selected patients, allogeneic or autologous BMT is an effective salvage therapy for NHL which recurs after autologous BMT.",
keywords = "BMT, Lymphoma, Relapse",
author = "{De Lima}, M. and {Van Besien}, {K. W.} and Giralt, {S. A.} and Khouri, {I. F.} and R. Mehra and Andersson, {B. S.} and D. Przepiorka and Gajewski, {J. L.} and M. Korbling and Champlin, {R. E.}",
year = "1997",
month = "1",
day = "2",
language = "English (US)",
volume = "19",
pages = "121--127",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma

AU - De Lima, M.

AU - Van Besien, K. W.

AU - Giralt, S. A.

AU - Khouri, I. F.

AU - Mehra, R.

AU - Andersson, B. S.

AU - Przepiorka, D.

AU - Gajewski, J. L.

AU - Korbling, M.

AU - Champlin, R. E.

PY - 1997/1/2

Y1 - 1997/1/2

N2 - We evaluated the response to and toxicity of allogeneic or autologous bone marrow transplantation (BMT) for patients with non-Hodgkin's lymphoma (NHL) who relapsed after autologous BMT. Since 1990, 172 patients have received autologous BMTs for NHL at the MD Anderson Cancer Center and 75 have relapsed. Twelve patients (median age, 42 years), with disease recurrence underwent either allogeneic BMT (eight patients) or a second autologous BMT (four patients). Ten patients received thiotepa, busulfan and cyclophosphamide as conditioning, one patient received cyclophosphamide and total body irradiation and one received BCNU, etoposide, Ara-c and melphalan. The median interval between the first and second transplants was 23.5 months (range 5-80 months). Three patients who underwent allogeneic BMT had refractory relapses, three had a responsive relapse and two were in complete response (CR) at the time of BMT. Five patients received peripheral blood stem cells and three patients, allogeneic bone marrow. Three patients are alive and disease-free at 25, 22 and 7 months after allogeneic BMT. Four patients died of treatment-related causes and one from disease recurrence. All four patients undergoing autologous BMT had responsive relapses. Three patients received peripheral blood stem cells and one patient bone marrow. Two patients are alive and disease-free at 12 and 30 months after autologous transplants. There were no treatment-related deaths; two patients died of disease recurrence. This retrospective study shows that in selected patients, allogeneic or autologous BMT is an effective salvage therapy for NHL which recurs after autologous BMT.

AB - We evaluated the response to and toxicity of allogeneic or autologous bone marrow transplantation (BMT) for patients with non-Hodgkin's lymphoma (NHL) who relapsed after autologous BMT. Since 1990, 172 patients have received autologous BMTs for NHL at the MD Anderson Cancer Center and 75 have relapsed. Twelve patients (median age, 42 years), with disease recurrence underwent either allogeneic BMT (eight patients) or a second autologous BMT (four patients). Ten patients received thiotepa, busulfan and cyclophosphamide as conditioning, one patient received cyclophosphamide and total body irradiation and one received BCNU, etoposide, Ara-c and melphalan. The median interval between the first and second transplants was 23.5 months (range 5-80 months). Three patients who underwent allogeneic BMT had refractory relapses, three had a responsive relapse and two were in complete response (CR) at the time of BMT. Five patients received peripheral blood stem cells and three patients, allogeneic bone marrow. Three patients are alive and disease-free at 25, 22 and 7 months after allogeneic BMT. Four patients died of treatment-related causes and one from disease recurrence. All four patients undergoing autologous BMT had responsive relapses. Three patients received peripheral blood stem cells and one patient bone marrow. Two patients are alive and disease-free at 12 and 30 months after autologous transplants. There were no treatment-related deaths; two patients died of disease recurrence. This retrospective study shows that in selected patients, allogeneic or autologous BMT is an effective salvage therapy for NHL which recurs after autologous BMT.

KW - BMT

KW - Lymphoma

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=0031014428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031014428&partnerID=8YFLogxK

M3 - Article

C2 - 9116608

AN - SCOPUS:0031014428

VL - 19

SP - 121

EP - 127

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -